9 research outputs found
Recommended from our members
Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study.
Funder: The Darwin Trust of EdinburghFunder: National Institute of Health [grant number R01 HL136528]BACKGROUND: We conducted a Mendelian randomisation (MR) study to investigate whether physical activity (PA) causes a reduction of colorectal cancer risk and to understand the contributions of effects mediated through changes in body fat. METHODS: Common genetic variants associated with self-reported moderate-to-vigorous PA (MVPA), acceleration vector magnitude PA (AMPA) and sedentary time were used as instrumental variables. To control for confounding effects of obesity, we included instrumental variables for body mass index (BMI), body fat percentage, waist circumference and arm, trunk and leg fat ratios. We analysed the effect of these instrumental variables in a colorectal cancer genome-wide association study comprising 31,197 cases and 61,770 controls of European ancestry by applying two-sample and multivariable MR study designs. RESULTS: We found decreased colorectal cancer risk for genetically represented measures of MVPA and AMPA that were additional to effects mediated through genetic measures of obesity. Odds ratio and 95% confidence interval (CI) per standard deviation increase in MVPA and AMPA was 0.56 (0.31, 1.01) and 0.60 (0.41, 0.88), respectively. No association has been found between sedentary time and colorectal cancer risk. The proportion of effect mediated through BMI was 2% (95% CI: 0, 14) and 32% (95% CI: 12, 46) for MVPA and AMPA, respectively. CONCLUSION: These findings provide strong evidence to reinforce public health measures on preventing colorectal cancer that promote PA at a population level regardless of body fatness
Disease consequences of higher adiposity uncoupled from its adverse metabolic effects using Mendelian randomisation
Background:
Some individuals living with obesity may be relatively metabolically healthy, whilst others suffer from multiple conditions that may be linked to adverse metabolic effects or other factors. The extent to which the adverse metabolic component of obesity contributes to disease compared to the non-metabolic components is often uncertain. We aimed to use Mendelian randomisation (MR) and specific genetic variants to separately test the causal roles of higher adiposity with and without its adverse metabolic effects on diseases.
Methods:
We selected 37 chronic diseases associated with obesity and genetic variants associated with different aspects of excess weight. These genetic variants included those associated with metabolically ‘favourable adiposity’ (FA) and ‘unfavourable adiposity’ (UFA) that are both associated with higher adiposity but with opposite effects on metabolic risk. We used these variants and two sample MR to test the effects on the chronic diseases.
Results:
MR identified two sets of diseases. First, 11 conditions where the metabolic effect of higher adiposity is the likely primary cause of the disease. Here, MR with the FA and UFA genetics showed opposing effects on risk of disease: coronary artery disease, peripheral artery disease, hypertension, stroke, type 2 diabetes, polycystic ovary syndrome, heart failure, atrial fibrillation, chronic kidney disease, renal cancer, and gout. Second, 9 conditions where the non-metabolic effects of excess weight (e.g. mechanical effect) are likely a cause. Here, MR with the FA genetics, despite leading to lower metabolic risk, and MR with the UFA genetics, both indicated higher disease risk: osteoarthritis, rheumatoid arthritis, osteoporosis, gastro-oesophageal reflux disease, gallstones, adult-onset asthma, psoriasis, deep vein thrombosis, and venous thromboembolism.
Conclusions:
Our results assist in understanding the consequences of higher adiposity uncoupled from its adverse metabolic effects, including the risks to individuals with high body mass index who may be relatively metabolically healthyDiabetes UK (17/0005594); Medical Research Council (MR/T002239/1)l; World Cancer Research Fund (IIG_2019_2009); Medical Research Council (MC_UU_00011/1); Diabetes UK (17/0005587); Cancer Research UK (C18281/A29019)
Preprint: Using genetics to uncouple higher adiposity from its adverse metabolic effects and understand its role in metabolic and non-metabolic disease
To understand the consequences of higher adiposity uncoupled from its adverse metabolic effects, we selected 37 diseases associated with obesity and genetic variants associated with different aspects of excess weight including metabolically “favourable adiposity” (FA) and “unfavourable adiposity” (UFA). Mendelian randomisation (MR) identified two sets of diseases. First, 12 conditions where the metabolic effect of higher adiposity is the likely primary cause of the disease. Here MR with the FA and UFA genetics showed opposing effects on risk of disease, including colorectal and ovarian cancer, and gout. Second, 7 conditions where the non-metabolic effects of excess weight (e.g. mechanical effect) is likely a cause. Here MR with the FA genetics, despite leading to lower metabolic risk, and MR with the UFA genetics, were both associated with higher disease risk, including osteoarthritis and venous thromboembolism. Individuals with high BMI are at higher risk of some diseases despite being relatively metabolically healt
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk
We performed a meta-analysis of five genome-wide association studies to identify common variants influencing colorectal cancer (CRC) risk comprising 8,682 cases and 9,649 controls. Replication analysis was performed in case-control sets totaling 21,096 cases and 19,555 controls. We identified three new CRC risk loci at 6p21 (rs1321311, near CDKN1A; P = 1.14 × 10 -10), 11q13.4 (rs3824999, intronic to POLD3; P = 3.65 × 10 -10) and Xp22.2 (rs5934683, near SHROOM2; P = 7.30 × 10 -10) This brings the number of independent loci associated with CRC risk to 20 and provides further insight into the genetic architecture of inherited susceptibility to CRC.</p